The HER2 CISH pharmDx ™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

Author： Foged Niels T   Brügmann Anja   Jørgensen Jan T  

Publisher： Informa Healthcare

ISSN： 1473-7159

Source： Expert Review of Molecular Diagnostics, Vol.13, Iss.3, 2013-04, pp. : 233-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-HER2 Cancer Therapy and Cardiotoxicity

By  

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4911-4919

Bentham Science Publishers

Access to resources Recommend Favorite

Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts

By Balandin Taras   Edelweiss Evelina   Andronova Natalia   Treshalina Elena   Sapozhnikov Alexander   Deyev Sergey  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 22-32

Springer Publishing Company

Access to resources Recommend Favorite

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

By Yeon Christina   Pegram Mark  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 391-409

Springer Publishing Company

Access to resources Recommend Favorite

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

By Zelnak Amelia B.   Wisinski Kari B.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 17-24

Blackwell Publishing

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Current and Future Treatment Strategies

By Engel Ryan H.   Kaklamani Virginia G.  

Drugs, Vol. 67, Iss. 9, 2007-01 ,pp. : 1329-1341

Adis International

Access to resources Recommend Favorite